Rezolute (RZLT) is poised for growth with key Phase 3 trial results ahead. Ersodetug targets both congenital and ...
Discover why Structure Therapeutics Inc. is rated Strong Buy after positive Aleniglipron phase 2b obesity data. Click for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback